Emory nonprofit starts GoFundMe campaign to help test coronavirus treatment

Feb. 27, 2020

Media Contact

Catherine Morrow

A GoFundMe charity campaign launched by Drug Innovation Ventures at Emory, a nonprofit biotech company owned by the university, will help accelerate testing for an antiviral compound that could treat the new coronavirus.


GoFundMe: End Pandemics Now

What if you could help fund a cure for coronavirus?

Drug Innovation Ventures at Emory (DRIVE) was founded to discover and develop antiviral drugs to anticipate and help end deadly pandemics and outbreaks caused by viruses.

Today, DRIVE has the most promising potential antiviral therapeutic for coronavirus that can be taken as a pill, making it easy to disseminate, a critical aspect in containing a pandemic. #EndPandemicsNow

View the GoFundMe campaign.

Drug Innovation Ventures at Emory (DRIVE), a nonprofit biotechnology company owned by Emory University, launched a GoFundMe charity campaign Feb. 27 to help accelerate testing for its antiviral compound that could potentially be used to treat the new coronavirus associated with the outbreak in China and spreading around the globe.

While a related treatment, administered via injection, is currently being evaluated for COVID-19 in China, DRIVE’s approach is centered around an oral pill. Having an effective treatment for COVID-19 in pill form would allow the treatment to be more easily distributed to patients around the globe, which is a vital component in ending the epidemic. 

DRIVE is developing the compound, designated EIDD-2801, which has shown efficacy against other coronaviruses such as SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus) and MERS-CoV (Middle East Respiratory Syndrome Coronavirus).

To date, the research has been primarily funded by government agencies for the treatment of Influenza, coronavirus, chikungunya and Venezuelan equine encephalitis virus. While great progress has been made due to this support, additional urgent funds are needed to accelerate testing and development in order to prove its safety and efficacy in humans and ultimately bring it to the general population.

“We are working extremely hard to move its development forward as fast as possible with the hope of helping to address the new conoravirus outbreak,” says George Painter, PhD, chief executive officer of DRIVE.

“In addition to its good activity against coronavirus, EIDD-2801 is one of the few antiviral agents that is not just a ‘one bug, one drug’ compound,” says Dennis Liotta, PhD, executive director of Emory Institute for Drug Development. “It’s active against multiple viruses including, inter alia, influenza and Ebola. This would make it a useful compound to prepare and store to help quell future pandemics.”

The funds will be used to accelerate the development of EIDD-2801 for the treatment of COVID-19 and to help develop other antivirals to address future pandemics.  

View the “End Pandemics Now” GoFundMe campaign.

 

About DRIVE:  DRIVE is a nonprofit LLC wholly owned by Emory University started as an innovative approach to drug development.  Operating like an early stage biotechnology company, DRIVE applies focus and industry development expertise to efficiently translate discoveries to address viruses of global concern. Learn more.

Tags

Recent News